Troy Wichterman Sells 4,151 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 4,151 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00. Following the sale, the chief financial officer now directly owns 116,809 shares of the company's stock, valued at approximately $2,920,225. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Troy Wichterman also recently made the following trade(s):

• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Stock Up 3.7 %

BLFS stock traded up $0.92 during mid-day trading on Monday, hitting $25.92. The stock had a trading volume of 222,832 shares, compared to its average volume of 348,620. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The company has a fifty day moving average of $26.59 and a 200 day moving average of $25.49. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -24.45 and a beta of 2.04.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the firm earned ($0.21) earnings per share. On average, equities analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in shares of BioLife Solutions by 1.1% during the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider's stock worth $84,097,000 after acquiring an additional 36,176 shares in the last quarter. Fred Alger Management LLC lifted its holdings in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock worth $41,386,000 after purchasing an additional 16,274 shares during the last quarter. State Street Corp boosted its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after purchasing an additional 95,788 shares during the period. Millennium Management LLC grew its holdings in BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of BioLife Solutions by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock valued at $23,028,000 after purchasing an additional 40,416 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BLFS has been the subject of several recent analyst reports. KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Benchmark reissued a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. Finally, HC Wainwright upped their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, BioLife Solutions has a consensus rating of "Moderate Buy" and a consensus target price of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.